Share

Watch how cancer survivors struggle to resume a normal life

On 31 March and 1 April 2016, EORTC held its 2nd Summit on Cancer Survivorship. You can now watch the presentations and panel discussions that addressed both societal and health issues that cancer survivors face to resume a normal life.

Thursday 31 March 2016 – Societal Aspects

Session 1: A newly discovered reality (Chairs: P. O’Donnell & R. Sullivan)

Session 2: Accessibility to Job, insurance and mortgage (Chairs: I. Lebrocquy & R. Stupp)

Session 3: Specificities related to survivors of childhood and young adolescent cancer (Chairs: F. Baron & G. Vassal)

Friday 1 April 2016 – Medical Aspects

Session 4: Lifestyle after cancer – How to intervene? (Chairs: E.C. Moser & S. Narbutas)

Session 5: Data collection and legal issues – Challenges (Chairs: J. Bogaerts & J. Reijneveld)

Session 6: Lifestyle after cancer – How to measure? (Chairs: G. Katz & L. van de Poll-Franse)

Session 7: The EORTC survivorship taskforce, the commitment, vision and future perspectives (Chairs: L. Liu & A. Waldmann)

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023